Prime medicine announces pricing of upsized public offering

Cambridge, mass., feb. 14, 2024 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. prime medicine has also granted the underwriters a 30-day option to purchase up to an additional 3,360,000 shares of its common stock. the gross proceeds to prime medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $140.0 million, excluding any exercise of the underwriters' option to purchase additional shares. all of the shares and pre-funded warrants in the offering are to be sold by prime medicine. the offering is expected to close on or about february 20, 2024, subject to satisfaction of customary closing conditions.
PRME Ratings Summary
PRME Quant Ranking